Anbio Net Income From Continuing Ops from 2010 to 2026
| NNNN Stock | 24.62 0.08 0.32% |
Net Income From Continuing Ops | First Reported 2010-12-31 | Previous Quarter 2.1 M | Current Value 3.4 M | Quarterly Volatility 1.8 M |
Check Anbio Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Anbio Biotechnology's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 407.5 K or Interest Income of 407.5 K, as well as many indicators such as Price To Sales Ratio of 32.57, Dividend Yield of 0.0 or PTB Ratio of 15.51. Anbio financial statements analysis is a perfect complement when working with Anbio Biotechnology Valuation or Volatility modules.
Anbio | Net Income From Continuing Ops | Build AI portfolio with Anbio Stock |
Evaluating Anbio Biotechnology's Net Income From Continuing Ops across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Anbio Biotechnology Class's fundamental strength.
Latest Anbio Biotechnology's Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Anbio Biotechnology Class over the last few years. It is Anbio Biotechnology's Net Income From Continuing Ops historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Anbio Biotechnology's overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Anbio Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | 2,978,691 | |
| Geometric Mean | 2,740,631 | |
| Coefficient Of Variation | 61.46 | |
| Mean Deviation | 881,000 | |
| Median | 2,535,813 | |
| Standard Deviation | 1,830,659 | |
| Sample Variance | 3.4T | |
| Range | 7.9M | |
| R-Value | 0.22 | |
| Mean Square Error | 3.4T | |
| R-Squared | 0.05 | |
| Significance | 0.41 | |
| Slope | 78,192 | |
| Total Sum of Squares | 53.6T |
Anbio Net Income From Continuing Ops History
About Anbio Biotechnology Financial Statements
Anbio Biotechnology investors utilize fundamental indicators, such as Net Income From Continuing Ops, to predict how Anbio Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 2.1 M | 3.4 M |
Pair Trading with Anbio Biotechnology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Anbio Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Anbio Biotechnology will appreciate offsetting losses from the drop in the long position's value.Moving against Anbio Stock
| 0.68 | CMB | Cambium Bio Earnings Call Tomorrow | PairCorr |
| 0.48 | DNTH | Dianthus Therapeutics | PairCorr |
| 0.47 | DNLI | Denali Therapeutics Earnings Call This Week | PairCorr |
| 0.4 | OB3 | OPTIBIOTIX HLTH PLC | PairCorr |
| 0.39 | 2CG | NANOSPHERE HEASCIENCES | PairCorr |
The ability to find closely correlated positions to Anbio Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Anbio Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Anbio Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Anbio Biotechnology Class to buy it.
The correlation of Anbio Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Anbio Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Anbio Biotechnology Class moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Anbio Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Anbio Biotechnology Correlation against competitors. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Will Biotechnology sector continue expanding? Could Anbio diversify its offerings? Factors like these will boost the valuation of Anbio Biotechnology. Anticipated expansion of Anbio directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Anbio Biotechnology data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.028 | Earnings Share 0.06 | Revenue Per Share | Quarterly Revenue Growth (0.22) | Return On Assets |
Understanding Anbio Biotechnology Class requires distinguishing between market price and book value, where the latter reflects Anbio's accounting equity. The concept of intrinsic value - what Anbio Biotechnology's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Anbio Biotechnology's price substantially above or below its fundamental value.
It's important to distinguish between Anbio Biotechnology's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Anbio Biotechnology should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Anbio Biotechnology's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.